Sweetenham John W
Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Hematol Oncol Clin North Am. 2008 Oct;22(5):965-78, ix. doi: 10.1016/j.hoc.2008.07.009.
Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of "highly aggressive" is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.
高度侵袭性淋巴瘤在成人中相对不常见，约占美国和西欧所有非霍奇金淋巴瘤的4%至5%。“高度侵袭性”这一类别通常仅限于前体T细胞和B细胞淋巴母细胞淋巴瘤/白血病以及伯基特淋巴瘤/白血病。淋巴母细胞淋巴瘤和伯基特淋巴瘤的治疗策略包括复杂、高强度的联合化疗方案，这些方案可能具有治愈性。与非霍奇金淋巴瘤的其他亚型一样，来自基因表达谱分析及相关技术的新数据有助于更精确地界定这些疾病实体，并识别潜在的新的合理治疗靶点。
